Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Omega Therapeutics Inc
(NQ:
OMGA
)
1.490
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Omega Therapeutics Inc
< Previous
1
2
Next >
Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research
August 14, 2024
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
August 06, 2024
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors
June 24, 2024
Former Merck veteran brings extensive expertise across corporate finance, business development and corporate licensing
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics To Participate In Two Upcoming Investor Conferences
May 30, 2024
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer
May 29, 2024
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers
May 08, 2024
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 06, 2024
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting
April 23, 2024
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control
April 09, 2024
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update
March 28, 2024
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024
March 06, 2024
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
December 04, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference
November 20, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis
November 13, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 09, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics to Participate in The Jefferies London Healthcare Conference
November 07, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller
October 31, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC
October 16, 2023
Combination of a MYC-targeting epigenomic controller with immune checkpoint or EGFR inhibitor enhanced anti-tumor activity in models of NSCLC
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics Announces Two Poster Presentations on Liver Inflammation and Fibrosis at AASLD’s The Liver Meeting® 2023
October 11, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 04, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial
September 26, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26
September 25, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics to Participate in Two Upcoming Investor Conferences
September 21, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics Announces Updates to its Board of Directors
August 29, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 03, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics Appoints Chris Schade to its Board of Directors
July 12, 2023
Accomplished Industry Veteran Brings Deep Strategic and Operational Expertise
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics to Participate in Two Upcoming Investor Conferences
June 01, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics Presents New Preclinical Data Demonstrating the Potential of Omega Epigenomic Controllers™ to Synergize with Immunotherapies at the ASCO 2023 Annual Meeting
May 31, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Omega Therapeutics Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 04, 2023
From
Omega Therapeutics
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.